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Complete separation of the [3H]ethylketocyclazocine ([3H]EKC) specific binding (K subtype) from tritiated 
Tyr-D-Ala*-Me-Phe4-Gly-o15 enkephalin (DAGO) and Tyr-D-Ala*-L-Leu5-enkephalin (DALA) binding (J- 
and h-subtypes, respectively) was achieved by Sepharose-6B chromatography and sucrose density gradient 
centrifugation of digitonin solubilized frog brain membranes. The apparent sedimentation coefficient (sZo,J 
for the K receptor-detergent complex was 13.1 S and the corresponding Stokes radius 64 A. The isolated 
fractions exhibited high affinity for EKC and bremazocine, whereas p- and d-specific ligands were unable 
to compete for the [3H]EKC binding sites, indicating that the K subtype represents a separate molecular 
entity from the p and 6 receptor sites. 
Opioid receptor subtype SolubiIization Separation Sucrose density gradient centrifugation 
Gel filtration Hydrodynamical parameters 
1. INTRODUCTION 
It is well known from pharmacological and 
biochemical studies that the opioid receptor system 
consists of multiple subtypes, i.e., c, 6, x, (7 [l-3]. 
Although it has recently been found by us and 
other laboratories that opioid receptors may 
display different molecular forms [4-71, there is 
controversy over their function and relationship to 
the different subtypes. 
We had described earlier solubilization of active 
opioid receptors with good yield from frog brain 
using digitonin [8]. Two distinct receptor popula- 
tions were found by sucrose density gradient 
ultracentrifugation and Sepharose-6B gel filtra- 
tion, using an opioid antagonist, [‘Hlnaloxone 
(labelling /I-, 6- and x-sites equally) in receptor 
Abbreviations: EKC, ethylketocyclazocine; DAGO, Tyr- 
D-Ala’-Me-Phe4-Gly-ol’-enkephalin; DALA, Tyr-D- 
Ala*-L-Leu’-enkephalin; DADLE, Tyr-D-Ala*-D-Leu’- 
enkephalin; PMSF, phenylmethylsulfonyl fluoride; 
CHAPS, 3-[(3-cholamidopropyl)dimethylammonio]-l- 
propanesulfonate 
binding assays [4]. In the present work selective, 
tritiated ligands were used for labelling the sub- 
types. One population of receptors with x 
specificity was identified and completely separated 
from the partially comigrating p and S sites. 
2. MATERIALS AND METHODS 
(Tyr-3.5-[3H])‘-D-Ala2-L-LeuSenkephalin ([3H]- 
DALA: 1.37 TBq/mmol; 37.3 Ci/mmol) was syn- 
thesized by Dr G. T&h [9]. [9-3H]Ethylketocyc- 
lazocine ([3H]EKC: 0.74 TBq/mmol; 19.9 Ci/ 
mmol) was purchased from New England Nuclear. 
(Tyr-3.5-[3H])‘-D-Ala2-MePhe4-Gly-o15 enkepha- 
lin ([‘HIDAGO): 1.67 TBq/mmol; 45 Ci/mmol, 
was from Amersham. Levorphanol was kindly 
donated by Hoffmann La Roche. EKC was pro- 
vided by Sterling Winthrop Research Institute. 
DAGO was a generous gift of Dr D. Rijmer, San- 
doz Ltd. DALA was synthesized by Dr K. Med- 
zihradszky et al., Central Res. Inst. for Chemistry, 
Budapest, Hungary. SepharosedB beads and 
HMW calibration kit were obtained from Phar- 
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macia. All other chemicals were of analytical 
grade. 
Particulate membrane fraction of frog (Rana 
escufenta) brain was prepared in buffer A (50 mM 
Tris-HCl (pH 7.4), 1 mM EDTA, 40 KIU/ml 
trasylol, 20pglml bacitracin, 1 mM PMSF) and 
solubilized in 1% digitonin as described earlier 181. 
Gel filtration of the solubilized supernatant was 
carried out on a Sepharose-6B column, which was 
equilibrated with buffer B (50 mM Tris-HCl (pH 
7.4), 100 mM NaCl, 1 mM EDTA and 0.05~0 
digitonin) and calibrated with Pharmacia HMW 
kit. 
Sucrose density gradients were prepared in buf- 
fer A containing 0.05% digitonin. Samples were 
centrifuged at 2~~ x g for 16 h at 4’C in a 
Beckman SW-41 Ti rotor. 
Aliquots of the sucrose density gradient and 
SepharoseQB fractions were incubated in buffer A 
with [3H]DAG0 for 40 min at 35°C [lo], 
[3H]DALA for 90 min at 0°C [9] and 13H]EKC for 
40 min at 25°C [3] in a final volume of 1 ml. 
Following incubation, the samples were directly 
filtered on polyethyleneimine-treated Whatman 
GFlG or GFlB fiiters [l 11, and washed twice with 
10 ml ice-cold 50 mM Tris-HCl (pH 7.4) buffer. 
Radioactivity was counted in a toluene-based scin- 
tillation cocktail. Specific binding was defined as 
the difference between total binding and binding in 
the presence of 10 pM unlabelled ligands. Measur- 
ing 13H]DAG0 binding 10pM levorphanol was 
used for demonstration of nonspecific binding. 
For determining 6 binding sites the cross-reactivity 
of [3H]DALA to thep binding sites was reduced by 
the addition of 10 nM unlabelled DAGO 131. For 
the demonstration of x binding sites, the cross- 
reactivity of [3H]EKC to both p and 6 binding sites 
was decreased by addition of 100 nM unlabelled 
DALA and DAGO. 
Protein concentrations were determined by the 
method of Bradford [12]. 
3. RESULTS AND DISCUSSION 
To establish the specificity of the previously 
observed distinct molecular forms of frog brain 
opioid receptors [4,8], subtype specific ligands - 
[3H]DAG0, 13H]DALA and 13H]EKC (with p, 6 
and x specificity) - were used for labelling the 
fractions of gel filtration and sucrose density gra- 
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dient centrifugation. All labelled ligands were used 
above saturating concentration. As shown in fig. 1, 
a single activity peak appeared with [3H]EKC 
specific binding on a SepharosedB column. These 
fractions (40-45) are completely separated from 
the t and S sites (measured by [3H]DAG0 and 
f3H]DALA specific binding). The Stokes radius of 
the x receptor-detergent complex was 64 A. The p 
and S subtypes comigrated and showed two distinct 
activity peaks with a higher and a lower Stokes 
radius. There was an earlier report on partial 
separation of x and p receptor subtypes from 
CHAPS extract of rat brain on a Sepharose CL-6B 
column [6]. They detected two populations of x 
receptors: one of them coincided with the p sub- 
type, whereas the other one partially separated 
from that. Because they were not able to recover 
the S subtype after solubilization, there is no infor- 
mation on the position and size of the 6 receptor. 
We have also estimated the molecular masses of 
the different subtypes by sucrose density gradient 
centrifugation. Similar to gel filtration, low 
digitonin concentration (0.05%) was used because 
the detergent interferes in the binding assay. The 
Sepharose 68 chromatography 
-I 
60 
Fraction number 
Fig. 1. SepharosedB gel filtration of digitonin extract of 
frog brain membranes. Solubilized supernatants (3 ml) 
were applied to a Sepharose-6B coiumn (1.2 x 100 cm) 
and eluted with buffer B at a constant flow rate of 
10 ml/h. 0.6-ml ahquots of the fractions were measured 
in duplicate for 10 nM [3H]DAG0, 10 nM [3H]DALA 
and 7 nM [‘H]EKC specific binding as described in 
section 2. Protein markers and their Stokes radii were as 
follows: thyroglobulin 85 A, ferritin 61 A, catalase 
52.2 A, aidolase 48.1 A and hemoglobin 24 A. This 
experiment was repeated 4 times. 
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Fig.2. Sucrose density gradient (lo-30%, w/w) 
ultracentrifugation of digitonin solubilized opioid 
binding sites from frog brain. 1 ml solubilized 
su~rnat~t or mixture of standard proteins were 
layered on top of the gradient. After centrifugation, 
0.5ml aliquots were assayed for 10 nm [3H]DAG0, 
10 nM [3H]DALA and 7 nM t3H]EKC specific binding 
as described in section 2. Protein markers for the 
estimation of sedimentation coefficient were as follows: 
thyrogiobulin (19.3 S). ferritin (15.4 S), catalase 
(11.3 S), hemoglobin (4.2 S). This experiment was 
replicated 4 times. 
separation of the x subtype by this method was 
also successful (fig.2) and the apparent sedimenta- 
tion coefficient @x& for the x subtype was found 
to be 13.1 S. 13H]EKC binding was observed in 
fraction 9-12, where the presence of h and S recep- 
tors was low. When measuring S receptors with a 
more specific ligand ([3HJDADLE) identical 
results were obtained. The separation oft and 6 
receptors could not be solved by this method, 
either. The recovery of the different subtypes in 
the solubilized preparation was about the same 
(basically no loss in activity). The distribution of 
the p, 6 and x receptors did not significantly 
change on the Sepharose column and sucrose den- 
sity gradient either. 
Itzhak et al. [5] recently published the separation 
of the x subtype from digitonin solubilized extract 
of guinea-pig brain and cerebellum. Because of the 
instability of their preparation, the gradient was 
run only for 2.5 h, which was insufficient for com- 
plete separation. Expressing their data in cpm/mg 
protein shows less separation. 
The specificity of our x receptor subtype was 
further proved by displacement experiments. 2 nM 
[3H]EKC was used for labelling the pooled frac- 
tions of sucrose density gradient (fractions 9-12) 
and SepharosedB column (fractions 40-45). 
Unlabelled EKC and bremazocine showed high af- 
finity (IGO 4 and 30 nM, respectively). ,u- and 6- 
selective ligands up to 10 pM concentration did not 
decrease the 13H]EKC binding considerably, in- 
dicating that the separated fractions contain the x 
subtype exclusively. 
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